Hydroxyprogesterone Caproate
Product Images NDC 47335-037

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Hydroxyprogesterone Caproate (NDC 47335-037). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-hydroxyprogesterone-caproate-figure-1 (Spl Hydroxyprogesterone Caproate Figure 1)

This appears to be a graph of the proportion of women who remain pregnant as a function of gestational age with hydroxyprogesterone caproate and control groups. The gestational age (in weeks) is plotted on the X-axis and the proportion of women remaining pregnant is shown on the Y-axis. There are two lines on the graph, one for the group given hydroxyprogesterone caproate and the other for the control group. The number at risk for each group is also shown.*

FDA Label Image

Spl-hydroxyprogesterone-caproate-showbox (Spl Hydroxyprogesterone Caproate Showbox)

This appears to be a description of a medication called Hydroxyprogesterone Caproate Injection, containing 250mg of Hydroxyprogesterone caproate USP, benzyl benzoate 46%, castor oil 28.6%, and benzy alcohol 2%, used for intramuscular administration. This medication is stored at 20 to 25°C and is intended for use within 5 weeks after first use. Full prescribing and patient information can be found in the package insert. The medication is distributed by Sun Pharmaceutical Industries, Inc. and is manufactured in India. There is an illegible section with some batch and expiration information.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.